Loading...
•
Dec 31, 2019
Alector Q4 2019 Earnings Report
Alector reported financial results for the fourth quarter and year ended December 31, 2019.
Key Takeaways
Alector reported a net loss of $30.5 million for the fourth quarter ended December 31, 2019, compared to a net loss of $17.4 million for the same period in 2018. Collaboration revenue for the quarter was $6.0 million, compared to $9.1 million for the same period in 2018. Cash, cash equivalents, and marketable securities were $353.1 million as of December 31, 2019.
Continued execution across immuno-neurology platform, with multiple clinical, regulatory and operational milestones achieved in 2019.
On track to initiate pivotal Phase 3 trial in patients with frontotemporal dementia with a progranulin mutation (FTD-GRN) in 2020.
Strengthened balance sheet with $240 million in gross proceeds from recent public offering.
Provides business continuity update regarding COVID-19.
Revenue by Segment
Forward Guidance
Alector is proactively monitoring and assessing the current COVID-19 global pandemic. The Company is focused on avoiding and minimizing delays to its business initiatives, with the safety and well-being of employees, patients and partners as its highest priority. Following the completion of its recent public follow-on offering, the Company is financially well-positioned to continue executing on its key business priorities.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...